Pomegranate phytoconstituents blunt the inflammatory cascade in a chemically induced rodent model of hepatocellular carcinogenesis

Journal of Nutritional Biochemistry

Volumn 24, Issue 1, 2013, Pages 178-187

  Bishayee, Anupam ^a   Thoppil, Roslin J ^b   Darvesh, Altaf S ^b   Ohanyan, Vahagn ^c   Meszaros, J Gary ^c   Bhatia, Deepak ^b  

^a American University of Health Sciences   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c Northeast Ohio Medical University   (United States)

Author keywords

Chemoprevention; Cyclooxygenase 2; Hepatocarcinogenesis; Inflammation; Nuclear factor kappaB; Pomegranate

Indexed keywords

3 NITROTYROSINE; CYCLOOXYGENASE 2; DIETHYLNITROSAMINE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER PREVENTION; CARDIOTOXICITY; ECHOCARDIOGRAPHY; EMULSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PHYTOCHEMISTRY; POMEGRANATE; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOMA, HEPATOCELLULAR; CYCLOOXYGENASE 2; DIETHYLNITROSAMINE; ECHOCARDIOGRAPHY; HEART; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; INFLAMMATION; LIVER; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PLANT EXTRACTS; PUNICACEAE; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE;

LYTHRACEAE; RATTUS; RODENTIA;

EID: 84870414528     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.04.009     Document Type: Article

References (58)

1. Center M.M., Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2011, 20:2362-2368.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
3. Kawanishi S., Hiraku Y., Pinlaor S., Ma N. Oxidative stress and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 2006, 387:365-372.
4. Marra M., Sordelli I.M., Lombardi A., Lamberti M., Tarantino L., Giudice A., et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 2011, 9:171.
5. Bartsch H., Montesano R. Relevance of nitrosamines to human cancer. Carcinogenesis 1984, 5:1381-1393.
6. Schütte K., Bornschein J., Malfertheiner P. Hepatocellular carcinoma - epidemiological trends and risk factors. Dig Dis 2009, 27:80-92.
7. Blonski W., Kotlyar D.S., Forde K.A. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010, 16:3603-3615.
8. Je Y., Schutz F.A.B., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10:967-974.
9. Bishayee A., Politis T., Darvesh A.S. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 2010, 36:43-53.
10. Morgan T.R. Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Recent Results Cancer Res 2011, 188:85-99.
11. Lansky E.P., Newman R.A. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol 2007, 109:177-206.
12. Jurenka J. Therapeutic application of pomegranate (Punica granatum L.): a review. Altern Med Rev 2008, 13:128-144.
13. Basu A., Penugonda K. Pomegranate juice: a heart-healthy fruit juice. Nutr Rev 2009, 67:49-56.
14. Faria A., Calhau C. The bioactivity of pomegranate: impact on health and disease. Crit Rev Food Sci Nutr 2011, 51:626-634.
15. Adhami V.M., Khan N., Mukhtar H. Cancer chemoprevention by pomegranate: laboratory and clinical evidence. Nutr Cancer 2009, 61:811-815.
16. Bishayee A., Bhatia D., Thoppil R.J., Darvesh A.S., Nevo E., Lansky E.P. Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. Carcinogenesis 2011, 32:888-896.
17. Li W., Khor T.O., Xu C., Shen G., Jeong W.S., Yu S., Kong A.N. Activation of Nrf2-antioxidant signaling attenuates NF-κB-inflammatory response and elicits apoptosis. Biochem Pharmacol 2008, 76:1485-1489.
18. Navarro S.L., Li F., Lampe J.W. Mechanisms of action of isothiocyanates in cancer chemoprevention: an update. Food Func 2011, 2:579-587.
19. Cervello M., Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 2006, 12:5113-5121.
20. Bishayee A., Barnes K.F., Bhatia D., Darvesh A.S., Carroll R.T. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev Res 2010, 3:753-763.
21. Luther D.J., Ohanyan V., Shamhart P.E., Hodnichak C.M., Sisakian H., Booth T.D., et al. Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Invest New Drugs 2011, 29:380-391.
22. Shishodia S., Aggarwal B.B. Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol 2002, 35:28-40.
23. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
24. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109:81-96.
25. Nair S., Doh S.T., Chan J.Y., Kong A.N., Cai B. Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer 2008, 99:2070-2082.
26. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
27. Roder D.M. The epidemiology of gastric cancer. Gastric Cancer 2002, 5:5-11.
28. Ahn B., Han B.S., Kim D.J., Ohshima H. Immunohistochemical localization of inducible nitric oxide synthase and 3-nitrotyrosine in rat liver tumors induced by N-nitrosodiethylamine. Carcinogenesis 1999, 20:1337-1344.
29. Calvisi D.F., Pinna F., Ladu S., Pellegrino R., Muroni M.R., Simile M.M., et al. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 2008, 29:1639-1647.
30. Zhao X., Zhang J.J., Wang X., Bu X.Y., Lou Y.Q., Zhang G.L. Effect of berberine on hepatocyte proliferation, inducible nitric oxide synthase expression, cytochrome P450 2E1 and 1A2 activities in diethylnitrosamine-and phenobarbital-treated rats. Biomed Pharmacother 2008, 62:567-572.
31. Crowell J.A., Steele V.E., Sigman C.C., Fay J.R. Is inducible nitric oxide synthase a target for chemoprevention?. Mol Cancer Ther 2003, 2:815-823.
32. Alvarez B., Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003, 25:295-311.
33. Morimoto R.I. Cells in stress: transcriptional activation of heat shock genes. Science 1993, 259:1409-1410.
34. Craig E.A., Weissman J.S., Horwich A.L. Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell. Cell 1994, 78:365-372.
35. Morimoto R.I., Tisseres A., Georgopoulos C. Heat shock proteins in biology and medicine 1994, Cold Spring Harbor Press, New York.
36. Jolly C., Morimoto R.I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000, 92:1564-1572.
37. Mosser D.D., Morimoto R.I. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23:2907-2918.
38. Helmbrecht K., Zeise E., Rensing L. Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 2000, 33:341-365.
39. Garrido C., Gurbuxani S., Ravagnan L., Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun 2001, 286:433-442.
40. Joo M., Chi J.G., Hyucksang L. Expressions of HSP70 and HSP27 in hepatocellular carcinoma. J Korean Med Sci 2005, 20:829-834.
41. Breinig M., Caldas-Lopes E., Goeppert B., Malz M., Rieker R., Bergmann F., et al. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 2009, 50:102-112.
42. Carr B.I., Huang T.H., Buzin C.H., Itakura K. Induction of heat shock gene expression without heat shock by hepatocarcinogens and during hepatic regeneration in rat liver. Cancer Res 1986, 46:5106-5111.
43. Tacchini L., Schiaffonati L., Rappocciolo E., Cairo G., Bernelli-Zazzera A. Expression pattern of the genes for different members of the heat-shock protein 70 family, ornithine decarboxylase, and c-Ha-ras during the early stages of hepatocarcinogenesis. Mol Carcinog 1989, 2:233-236.
44. Shiota G., Okubo M., Noumi T., Noguchi N., Oyama K., Takano Y., et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999, 46:407-412.
45. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18:7908-7916.
46. Koga H. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?. Cancer 2003, 98:661-667.
47. Kern M.A., Haugg A.M., Koch A.F., Schilling T., Breuhahn K., Walczak H., et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 2006, 66:7059-7066.
48. Li J., Chen X., Dong X., Xu Z., Jiang H., Sun X. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells. J Gastroenterol Hepatol 2006, 21:1814-1820.
49. Rahman M.A., Dhar D.K., Yamaguchi E., Maruyama S., Sato T., Hayashi H., et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001, 7:1325-1332.
50. Marquez-Rosado L., Trejo-Solis M.C., Garcia-Cuellar C.M., Villa-Trevino S. Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol 2005, 43:653-660.
51. Hu K.Q. Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002, 139:234-243.
52. Jadeja R.N., Thounaojam M.C., Patel D.K., Devkar R.V., Ramachandran A.V. Pomegranate (Punica granatum L.) juice supplementation attenuates isoproterenol-induced cardiac necrosis in rats. Cardiovasc Toxicol 2010, 10:174-180.
53. Hassanpour Fard M., Ghule A.E., Bodhankar S.L., Dikshit M. Cardioprotective effect of whole fruit extract of pomegranate on doxorubicin-induced toxicity in rat. Pharm Biol 2011, 49:377-382.
54. Karin M. Nucleur factor-KappaB in cancer development and progression. Nature 2006, 441:431-436.
55. Courtois G., Gilmore T.D. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006, 25:6831-6843.
56. Tazawa R., Xu X.M., Wu K.K., Wang L.H. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 1994, 203:190-199.
57. Rahman M.A., Dhar D.K., Masunaga R., Yamanoi A., Kohno H., Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 2006, 60:2085-2089.
58. Ueno S., Aoki D., Kubo F., Hiwatashi K., Matsushita K., Oyama T., et al. Roxithromycin inhibits constitutive activation of nuclear factor kappaB by diminishing oxidative stress in a rat model of hepatocellular carcinoma. Clin Cancer Res 2005, 11:5645-5650.